[go: up one dir, main page]

UY29713A1 - Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones - Google Patents

Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones

Info

Publication number
UY29713A1
UY29713A1 UY29713A UY29713A UY29713A1 UY 29713 A1 UY29713 A1 UY 29713A1 UY 29713 A UY29713 A UY 29713A UY 29713 A UY29713 A UY 29713A UY 29713 A1 UY29713 A1 UY 29713A1
Authority
UY
Uruguay
Prior art keywords
applications
pharmaceutical composition
composition containing
piperidine derivative
derivative salt
Prior art date
Application number
UY29713A
Other languages
English (en)
Inventor
Bo-Goran Josefsson
Julien Giovannini
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29713A1 publication Critical patent/UY29713A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona hemifumarato de N-(2-(((2S)-3-((1-(4-clorobencil)piperidin-4-il)amino)-2-hidroxi-2-metilpropil)oxi)-4-hidroxifenil)acetamida o un solvato del mismo, composición farmacéuticas que contienen dicha sal o solvato y el uso de la sal o solvato en terapia.
UY29713A 2005-08-02 2006-07-31 Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones UY29713A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501769 2005-08-02

Publications (1)

Publication Number Publication Date
UY29713A1 true UY29713A1 (es) 2007-02-28

Family

ID=37708913

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29713A UY29713A1 (es) 2005-08-02 2006-07-31 Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones

Country Status (16)

Country Link
US (1) US20080176902A1 (es)
EP (1) EP1912944A1 (es)
JP (1) JP2009503066A (es)
KR (1) KR20080031370A (es)
CN (1) CN101238104A (es)
AR (1) AR056013A1 (es)
AU (1) AU2006276346A1 (es)
BR (1) BRPI0614535A2 (es)
CA (1) CA2617406A1 (es)
IL (1) IL188484A0 (es)
MX (1) MX2008001114A (es)
NO (1) NO20081079L (es)
TW (1) TW200734305A (es)
UY (1) UY29713A1 (es)
WO (1) WO2007015668A1 (es)
ZA (1) ZA200800488B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3421323B2 (ja) * 1998-11-20 2003-06-30 エフ．ホフマン−ラ ロシュ アーゲー ピペリジンｃｃｒ−３受容体拮抗薬
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ZA200800488B (en) 2008-12-31
IL188484A0 (en) 2008-04-13
BRPI0614535A2 (pt) 2011-04-05
CA2617406A1 (en) 2007-02-08
EP1912944A1 (en) 2008-04-23
KR20080031370A (ko) 2008-04-08
TW200734305A (en) 2007-09-16
AU2006276346A1 (en) 2007-02-08
AR056013A1 (es) 2007-09-12
MX2008001114A (es) 2008-03-11
US20080176902A1 (en) 2008-07-24
NO20081079L (no) 2008-02-29
JP2009503066A (ja) 2009-01-29
CN101238104A (zh) 2008-08-06
WO2007015668A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
HUS2000011I1 (hu) A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
AR053547A1 (es) Composiciones de sales anti transpirantes de aluminio o aluminio- zirconio de eficacia acrecentada que contienen sal (es) de calcio y betaina
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CY1122429T1 (el) Αμορφη υδροχλωρικη λερκανιδιπινη
CY1110221T1 (el) Σταθερα φαρμακευτικα σκευασματα νατριουχου μοντελουκαστης
CL2004000409A1 (es) Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
UY28348A1 (es) Compuestos novedosos
CR10227A (es) Sal de ácido succínico del éster 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilmino]metil}-5-metoxifenilcarbamoil)etil]piperidin-4-ílicodelácidobifenil2ilcarbámicoysuusoparaeltratamientodetrastornospulmonar
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
TW200736227A (en) New compounds III
SE0402284D0 (sv) New heterocyclic amides
ECSP088219A (es) Nueva sal i
UY29713A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
EA200602017A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
EP1867329A3 (en) 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
CL2006003449A1 (es) Compuestos derivados de n-(fluoro-pirazinil)-fenilsulfonamidas; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del asma.
EP1987834A3 (en) Substituted piperidines as therapeutic compounds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160830